SELLAS Life Sciences (SLS) Return on Capital Employed (2012 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Return on Capital Employed of 35.03% for Q1 2026, up 10252.0% year-over-year from N/an in Q1 2025, and up 28.21% quarter-over-quarter from 48.8% in Q4 2025.
SELLAS Life Sciences (SLS) Return on Capital Employed (2012 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Return on Capital Employed for 13 consecutive years, with 35.03% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 10252.0% year-over-year to 35.03%; the TTM figure through Mar 2026 stood at 35.03% (up 10252.0% YoY), while the FY2025 annual figure was 67.53%, up 88295.0% from the prior year.
- Return on Capital Employed rose to 35.03% in Q1 2026 per SLS's latest filing, from 48.8% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 575.3% in Q4 2023 and bottomed at 4073.41% in Q1 2024.
- Historically, Return on Capital Employed has averaged 558.39% across 5 years, with a median of 300.31% in 2022.
- Annual changes were most pronounced in 2024 — Return on Capital Employed plunged 368975 bps — and 2025, when it jumped 393586 bps.
- SELLAS Life Sciences' Return on Capital Employed stood at 527.21% in 2022, then surged by 209 bps to 575.3% in 2023, then slumped by 141 bps to 234.15% in 2024, then jumped by 79 bps to 48.8% in 2025, then increased by 28 bps to 35.03% in 2026.
- Business Quant data shows SLS's Return on Capital Employed at 35.03% in Q1 2026, 48.8% in Q4 2025, and 74.81% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | -28.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.82% |
| Mar 31, 2026 | -35.03% |
| Dec 31, 2025 | -48.80% |
| Sep 30, 2025 | -74.81% |
| Jun 30, 2025 | -98.38% |
| Mar 31, 2025 | -137.55% |
| Dec 31, 2024 | -234.15% |
| Sep 30, 2024 | -321.33% |
| Jun 30, 2024 | -450.16% |
| Mar 31, 2024 | -4,073.41% |
| Dec 31, 2023 | 575.30% |
| Sep 30, 2023 | -2,459.96% |
| Jun 30, 2023 | -354.55% |
| Mar 31, 2023 | -383.66% |
| Dec 31, 2022 | -527.21% |
| Sep 30, 2022 | -266.56% |
| Jun 30, 2022 | -300.31% |
| Mar 31, 2022 | -301.95% |
| Dec 31, 2021 | -93.23% |
| Sep 30, 2021 | -50.28% |